If you're on Tysabri, you likely know that regular monitoring is key to staying safe. This follow-up care typically includes periodic MRI scans and blood tests to watch for signs of PML. Building on decades of research into biologic therapies, this page explains what each checkup entails and how it helps protect your health.
Tysabri (natalizumab) is a monoclonal antibody indicated as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use is associated with a significantly increased risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV). PML typically occurs only in immunocompromised patients and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration has assigned a boxed warning to Tysabri due to this risk, emphasizing that healthcare professionals must monitor patients for any new signs or symptoms suggestive of PML and withhold dosing immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three established risk factors increase the likelihood of PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be weighed against expected benefits when initiating or continuing therapy. Because of this risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
The clinical presentation of PML can be variable, often including progressive neurological deficits such as weakness, cognitive decline, visual disturbances, and coordination problems. Diagnosis typically involves brain MRI and detection of JCV DNA in cerebrospinal fluid. Early recognition is critical, as prompt discontinuation of Tysabri may improve outcomes. However, PML has been reported even after discontinuation of Tysabri in patients who did not have findings suggestive of PML at the time of stopping treatment. Therefore, monitoring for new signs or symptoms should continue for at least six months following discontinuation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Prognosis for Tysabri-associated PML is generally poor, with the infection usually leading to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The severity of outcomes is influenced by factors such as the extent of brain involvement, the patient's immune status, and the timeliness of intervention. Treatment for severe PML after Tysabri exposure focuses on supportive care and restoration of immune function. There is no specific antiviral therapy approved for PML, but strategies may include plasma exchange or immunoadsorption to accelerate clearance of natalizumab from the bloodstream, thereby allowing immune reconstitution. This approach can lead to immune reconstitution inflammatory syndrome (IRIS), which may exacerbate neurological symptoms and requires careful management with corticosteroids. The overall prognosis remains guarded, and many patients experience significant long-term neurological deficits.
The timeline between Tysabri exposure and documented harm varies. PML can occur during treatment, often after prolonged use, but cases have also been reported after discontinuation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The risk increases with cumulative exposure, particularly beyond two years. This latency complicates risk assessment and underscores the need for ongoing vigilance even after therapy ends. Adequacy of warnings regarding Tysabri and PML is addressed through the boxed warning, which clearly states the increased risk and the usual fatal or disabling outcome (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The prescribing information details risk factors and mandates monitoring and immediate withholding of dosing at first suspicion of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The TOUCH Prescribing Program further restricts distribution to ensure prescribers and patients are informed of the risks. Despite these measures, PML remains a serious adverse event with devastating consequences, highlighting the importance of careful patient selection and adherence to monitoring protocols.
In summary, Tysabri-associated PML carries a grave prognosis, with most cases resulting in death or severe disability. Treatment focuses on supportive care and immune reconstitution, but outcomes are often poor. The risk is heightened by anti-JCV antibody positivity, longer treatment duration, and prior immunosuppressant use. Warnings are prominently placed in the prescribing information, and a restricted distribution program aims to mitigate risk. However, the potential for PML after discontinuation necessitates prolonged monitoring. Clinicians must balance the therapeutic benefits of Tysabri against this serious risk when considering treatment.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
The prognosis for Tysabri-associated PML is generally poor, with the infection usually leading to death or severe disability. Outcomes depend on factors such as the extent of brain involvement, immune status, and timeliness of intervention. Treatment focuses on supportive care and immune reconstitution, but many patients experience significant long-term neurological deficits.
Three established risk factors increase the likelihood of PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors should be weighed against expected benefits when initiating or continuing therapy.
Diagnosis typically involves brain MRI and detection of JCV DNA in cerebrospinal fluid. Early recognition is critical, as prompt discontinuation of Tysabri may improve outcomes. Monitoring for new signs or symptoms should continue for at least six months following discontinuation.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.